What's in NEMA Research, Inc.'s pipeline?

NEMA Research, Inc. has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with NEMA Research, Inc.'s portfolio?

Top competitors by shared drug class: Centre for Addiction and Mental Health, Eldon Loh, MD, University of Calgary.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/nema-research-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

NEMA Research, Inc. — Portfolio Competitive Intelligence Brief

NEMA Research, Inc. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Cesamet™ (nabilone)	Cesamet™ (nabilone)	marketed	Synthetic cannabinoid	CB1 and CB2 cannabinoid receptors	Oncology, Anesthesia

Therapeutic area mix

Oncology, Anesthesia · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Centre for Addiction and Mental Health · 1 shared drug class
Eldon Loh, MD · 1 shared drug class
University of Calgary · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for NEMA Research, Inc.:

Cite this brief

Drug Landscape (2026). NEMA Research, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nema-research-inc. Accessed 2026-05-16.